Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in infants with achondroplasia at risk of cervicomedullary compression
NCT04554940Phase 2Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Dec 2027
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical. Started Oct 2020; status: active, not recruiting.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT04554940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554940.